SpringWorks Therapeutics, Inc.
SWTX
$44.72
-$0.21-0.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 24.84% | 22.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.84% | -17.46% | |||
| Cost of Revenue | 66.24% | 36.20% | |||
| Gross Profit | 21.83% | -19.76% | |||
| SG&A Expenses | 25.16% | 6.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.25% | 2.47% | |||
| Operating Income | -40.40% | -28.98% | |||
| Income Before Tax | -44.40% | -34.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.40% | -34.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.40% | -34.10% | |||
| EBIT | -40.40% | -28.98% | |||
| EBITDA | -40.78% | -29.45% | |||
| EPS Basic | -44.19% | -33.83% | |||
| Normalized Basic EPS | -44.20% | -33.84% | |||
| EPS Diluted | -44.19% | -33.83% | |||
| Normalized Diluted EPS | -44.20% | -33.84% | |||
| Average Basic Shares Outstanding | 0.15% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.15% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||